Neural Implant / BCI Device Patent Landscape 2026
The neural implant and BCI device patent space is heavily concentrated, with Boston Scientific Neuromodulation Corp alone commanding the largest share among the top hundred filers. The field has reached a mature, plateau-phase, with electrotherapy hardware as the dominant technical route and adjacent digital-health and AI branches remaining comparatively sparse.
Boston Scientific leads a highly concentrated field with a clear tier gap
Boston Scientific Neuromodulation Corp ranks first with 474 patent records, more than twice the combined count of the next two filers — Medtronic Inc at 159 and LivaNova USA Inc at 139. This single-entity dominance is unusual even in concentrated medtech segments.
The top five filers — Boston Scientific Neuromodulation Corp, Medtronic Inc, LivaNova USA Inc, LivaNova PLC, and NeuroPace Inc — together account for 49% of the hundred largest filers’ combined total, confirming tight concentration at the top with a steep drop-off beyond the leading trio.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Boston Scientific Neuromodulation Corp | 474 | |
| 2 | Medtronic Inc | 159 | |
| 3 | LivaNova USA Inc | 139 | |
| 4 | LivaNova PLC | 131 | |
| 5 | NeuroPace Inc | 94 | |
| 6 | Axonics Inc | 53 | |
| 7 | University of Louisville Research Foundation Inc | 51 | |
| 8 | Regents of the University of California | 41 | |
| 9 | California Institute of Technology | 39 | |
| 10 | Shiratronics Inc | 39 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | SetPoint Medical Corp | 32 | |
| 12 | Realeve LLC | 30 | |
| 13 | Alfred E. Mann Foundation for Scientific Research | 29 | |
| 14 | BIOTRONIK SE & CO KG | 28 | |
| 15 | ImThera Medical Inc | 28 | |
| 16 | Greatbatch Ltd | 28 | |
| 17 | Capri Medical Ltd | 21 | |
| 18 | Saluda Medical Pty Ltd | 20 | |
| 19 | Verily Life Sciences LLC | 20 | |
| 20 | Autonomic Technologies Inc | 19 |
Boston Scientific’s position, built predominantly on A61N electrotherapy filings, creates a dense prior-art thicket in core stimulation-device claims. Challengers and new entrants are largely differentiated by indication focus (e.g., sacral neuromodulation for Axonics Inc, closed-loop seizure detection for NeuroPace Inc) or by academic research pipelines rather than broad platform portfolios.
The most recent 18–24 months of filings are subject to standard publication lag and are likely undercounted; the figures for 2025–2026 should not be interpreted as a definitive slowdown. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity has plateaued post-2022 peak; electrotherapy dominates, digital health is thin
Annual filing volume and the technology branch mix together reveal a maturing core and nascent adjacencies that have not yet attracted sustained filing volume.
Annual filing trend
Filings peaked in 2022 at 140 and have since eased, with 2023 at 91 and 2024 at 101. The multi-year window still shows positive growth of 5%, consistent with a plateau rather than a structural decline. The 2025 partial figure of 111 and the 2026 stub of 11 reflect publication lag and should not be read as a recovery or further dip.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (Electrotherapy and radiation therapy) is overwhelmingly dominant, reflecting the field’s roots in implantable pulse generators and electrode arrays. A61B (Diagnosis and surgery) is a meaningful secondary branch. Digital-processing classes — G06F, G16H, and G06N — are present but collectively thin, signaling that software-defined neurostimulation and AI-driven closed-loop control remain early-stage in terms of dedicated patent coverage.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Modular brain-computer interface
A module for a brain-computer interface includes means for measuring neuronal activity in at least a portion of a population of neurons; means for stimulating at least the portion of the population of neurons; and means for local processing adapted to pre-analyze measured neuronal activity. A hub for a brain-computer interface includes means for powering a… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Treatment of motility disorders by nerve stimulation | 1,312 |
| 2 | Therapeutic treatment of migraine symptoms by stim… | 1,083 |
| 3 | Automatic activation of a neurostimulator device u… | 899 |
| 4 | Implantable stimulator system and method for treat… | 891 |
| 5 | Method to enhance cardiac capillary growth in hear… | 860 |
| 6 | System and method for adaptive brain stimulation | 802 |
| 7 | Treatment of congestive heart failure and autonomi… | 792 |
| 8 | Obesity treatment with electrically induced vagal … | 640 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the patent structure means for R&D investment decisions
Concentration, lifecycle stage, and technology-branch sparsity each carry distinct implications for teams deciding where to build IP positions or identify freedom-to-operate.
Field is at plateau — core electrotherapy IP is dense
Annual filings have plateaued near the 2022 peak with only 5% recent-window growth, placing the field firmly in the Maturity stage. Core A61N stimulation-device claims are heavily populated by the leading filers, raising freedom-to-operate risk for new entrants seeking broad platform coverage. Differentiation through indication-specific or closed-loop algorithmic claims offers a more viable path than broad hardware claims.
Lifecycle: MaturitySingle-entity dominance limits partnership optionality
Boston Scientific Neuromodulation Corp’s 474-record position is more than three times that of third-ranked LivaNova USA Inc (139 records). This degree of concentration means most cross-licensing negotiations in the core electrotherapy space run through a single counterparty. Mid-tier filers — Axonics Inc, NeuroPace Inc, and the University of Louisville Research Foundation — have narrower but potentially complementary portfolios that could be acquisition or licensing targets.
Concentration: HighAcademic tripartite cluster anchors the research pipeline
The most active co-filing relationships involve the Regents of the University of California, California Institute of Technology, and the University of Louisville Research Foundation, with co-filing counts of 32, 30, and 29 respectively across the three pairings. The University of Southern California extends this west-coast academic cluster. Cyberonics (LivaNova’s predecessor entity) co-filed with East Tennessee State University, indicating a separate clinical-research channel. These collaborations represent potential early-access points for industrial partners seeking emerging neurostimulation modalities ahead of commercialization.
Collaboration: Academic clusterUS-centric protection; Asia-Pacific coverage is thin
The United States office leads jurisdiction coverage with 1,051 patent records, followed by Europe (EPO) at 348 and WIPO PCT filings at 254. China has 145 records and Australia 131, while Japan holds only 37 and South Korea 18. The relative sparsity in Japan and South Korea — active medtech manufacturing markets — suggests potential gaps in protection, or alternatively that competitive risk from those markets has not been prioritized. Any expansion strategy should assess whether key families have been validated in those jurisdictions.
Geography: US-dominantGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Regents of the University of California | California Institute of Technology | 32 |
| University of Louisville Research Foundation Inc | California Institute of Technology | 30 |
| University of Louisville Research Foundation Inc | Regents of the University of California | 29 |
| Regents of the University of California | University of Southern California | 4 |
| California Institute of Technology | University of Southern California | 3 |
| Cyberonics Inc | East Tennessee State University | 2 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Boston Scientific anchors the field; Axonics is the only top filer gaining momentum
Among the filers with available momentum data, only Axonics Inc is growing its recent filing rate, while the two largest incumbents have both seen significant recent declines.
Boston Scientific Neuromodulation Corp
The dominant filer with 474 patent records, concentrated overwhelmingly in A61N electrotherapy (463 records), with secondary coverage in A61B diagnosis and surgery (86 records) and G06F digital data processing (44 records). Recent filing momentum has declined 30% versus the prior three-year period, suggesting the portfolio is maturing rather than actively expanding. The digital-processing filings, though a small share, may indicate early moves toward algorithm-defined stimulation.
patent records: 474Axonics Inc
Ranked sixth with 53 patent records, Axonics Inc is focused on sacral neuromodulation (54 A61N records) with secondary coverage in A61B surgery and diagnostics (11 records) and power supply systems H02J (8 records), reflecting its rechargeable implant differentiation. It is the only top-tier applicant with positive recent momentum, up 17% versus the prior period, making it the most actively expanding commercial filer in the current window.
patent records: 53| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Boston Scientific Neuromodulation Corp | 37 | ▼ -30% |
| Medtronic Inc | 6 | ▼ -60% |
| NeuroPace Inc | 3 | ▲ new entrant |
| Axonics Inc | 14 | ▲ +17% |
| LivaNova USA Inc | 7 | ▼ -78% |
| University of Louisville Research Foundation Inc | 3 | ▲ new entrant |
| Regents of the University of California | 12 | ▲ new entrant |
| California Institute of Technology | 3 | ▲ new entrant |
Digital health informatics and AI-driven control are under-served adjacent branches
Several IPC branches adjacent to the dominant electrotherapy core have low patent-record counts relative to their plausible technical relevance, making them worth monitoring as potential differentiation areas.
G16H · Healthcare Informatics
With 103 patent records, G16H is one of the thinner branches relative to the scale of the core A61N corpus. Closed-loop BCI systems increasingly depend on patient-data platforms, remote programming, and outcome-tracking software — functionality that maps directly to G16H. The low filing density suggests most applicants have not yet pursued dedicated healthcare-informatics claims alongside their device patents, leaving potential coverage gaps for software-forward entrants or digital-health platform companies entering the neuromodulation space.
Search this in Eureka →G06N · Computing Based on AI Models
Only 38 patent records fall under G06N, despite growing industry interest in machine-learning-driven adaptive stimulation and neural-signal decoding — core capabilities for next-generation BCI devices. The sparse coverage, combined with the academic collaboration cluster (UC system, Caltech, University of Louisville) that is actively filing in signal-processing spaces, suggests this branch is at an early-formative stage. Industrial applicants willing to build AI-model claims alongside hardware filings may find relatively open ground, though the technical and regulatory path to validated adaptive algorithms remains demanding.
Search this in Eureka →How leading filers differ by technology route
Route coverage across the main technology branches in the current evidence set.
| Player | A61N 1 · Electrotherapy & radiation therapy | A61B 5 · Diagnosis & surgery | G06F 3 · Electric digital data processing | G16H 20 · Healthcare informatics | G16H 40 · Healthcare informatics |
|---|---|---|---|---|---|
| Boston Scientific Neuromodulation Corp | Strong · 463 | Emerging · 86 | Emerging · 8 | Emerging · 28 | Emerging · 29 |
| Medtronic Inc | Strong · 156 | Absent | Absent | Absent | Absent |
| NeuroPace Inc | Strong · 86 | Moderate · 29 | Absent | Emerging · 2 | Emerging · 2 |
| LivaNova USA Inc | Strong · 54 | Moderate · 16 | Absent | Moderate · 11 | Emerging · 7 |
| University of Louisville Research Foundation Inc | Strong · 50 | Strong · 35 | Absent | Absent | Absent |
| Regents of the University of California | Strong · 42 | Strong · 26 | Emerging · 2 | Absent | Absent |
Frequently asked questions
The analysis covers 1,020 patent families. Jurisdiction and IPC branch counts are reported at the patent-record level, so those figures can exceed the family total because a single family may be validated in multiple countries or classified under multiple technology branches.
Boston Scientific Neuromodulation Corp is the dominant filer with 474 patent records, more than three times the count of the third-ranked applicant, LivaNova USA Inc at 139 records.
The field is at the Maturity stage. Annual filings peaked in 2022 at 140 and have since eased, though the multi-year window still shows 5% growth. Core electrotherapy device claims are densely populated by incumbent filers.
The United States leads with 1,051 patent records. Europe (EPO) is second at 348, followed by WIPO PCT at 254. China has 145 records. Japan (37) and South Korea (18) are comparatively thin, which may represent gaps in protection coverage for those markets.
The most active co-filing relationships are between the Regents of the University of California and California Institute of Technology (32 co-filings), the University of Louisville Research Foundation and California Institute of Technology (30 co-filings), and the University of Louisville Research Foundation and the Regents of the University of California (29 co-filings).
G16H (Healthcare informatics) and G06N (Computing based on AI models) are the most notable under-served adjacent branches, with 103 and 38 patent records respectively. Both are plausibly relevant to closed-loop BCI systems and adaptive stimulation but remain thinly covered compared to the core A61N electrotherapy corpus.
Ready to map your own neural implant and BCI patent landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.